Alzheimer and cardiovascular genetic scores and cognition: the FINGER randomized controlled trial - Scorecard - MDSpire

Alzheimer and cardiovascular genetic scores and cognition: the FINGER randomized controlled trial

  • By

  • Gazi Saadmaan

  • Maria Carolina Dalmasso

  • Maleeha Maria

  • Jenni Lehtisalo

  • Mikko Hiltunen

  • Minna U Kaikkonen

  • Esko Levälahti

  • Francesca Mangialasche

  • Markus Perola

  • Alfredo Ramirez

  • Ruth Stephen

  • Tiia Ngandu

  • Miia Kivipelto

  • Alina Solomon

  • August 6, 2025

  • 0 min

Share

Clinical Scorecard: Cognitive Impact of Alzheimer’s and Cardiovascular Genetic Risk Scores: Findings from the FINGER Randomized Controlled Trial

At a Glance

CategoryDetail
ConditionAlzheimer's disease and coronary artery disease
Key MechanismsGenetic predisposition (APOE ε4 allele, polygenic risk scores) and modifiable lifestyle factors influencing cognition and disease risk
Target PopulationOlder adults aged 60–77 years at risk for dementia without baseline dementia
Care SettingCommunity-based multidomain lifestyle intervention versus regular health advice

Key Highlights

  • Multidomain lifestyle intervention over 2 years improved cognition in at-risk older adults.
  • Genetic risk scores for Alzheimer's disease (AD-GRS) and coronary artery disease (CAD-GRS) did not significantly modify overall intervention effects.
  • Higher AD-GRS females showed greater cognitive benefits from the intervention compared to lower-risk females and males.

Guideline-Based Recommendations

Diagnosis

  • Use genome-wide association study data to calculate Alzheimer's disease and coronary artery disease genetic risk scores (AD-GRS, CAD-GRS) for risk stratification.

Management

  • Implement multidomain lifestyle interventions targeting multiple modifiable risk factors to improve cognition in older adults at risk for dementia.
  • Do not exclude individuals with high genetic risk (APOE4 carriers or high AD-GRS/CAD-GRS) from lifestyle interventions as they may benefit equally or more.

Monitoring & Follow-up

  • Assess cognitive changes longitudinally using comprehensive neuropsychological test batteries.
  • Consider sex differences when evaluating intervention effects in genetically at-risk populations.

Risks

  • Genetic susceptibility does not negate benefits of lifestyle interventions; no increased risk from intervention in high genetic risk groups reported.

Patient & Prescribing Data

Community-dwelling older adults aged 60–77 years at risk for dementia without baseline dementia

Multidomain lifestyle interventions can yield cognitive benefits regardless of genetic risk status; females with higher AD-GRS may experience greater benefit.

Clinical Best Practices

  • Incorporate multidomain lifestyle interventions addressing diet, exercise, cognitive training, and vascular risk management for dementia prevention.
  • Use genetic risk scores as exploratory tools to tailor prevention strategies but do not limit intervention access based on genetic risk alone.
  • Recognize potential sex differences in response to interventions among genetically at-risk individuals.
  • Continue research to validate genetic risk score impacts across diverse populations and trials.

References

Original Source(s)

Related Content